Literature DB >> 22246283

(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.

Orlando M Gutiérrez1, Kelsey T Smith, Allison Barchi-Chung, Neha M Patel, Tamara Isakova, Myles Wolf.   

Abstract

BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 (FGF23) regulates phosphorus and vitamin D metabolism. Parathyroid hormone (PTH) infusion for 24 hours stimulated FGF23 secretion in healthy volunteers. The extent to which this was due to a direct stimulatory effect of PTH versus an indirect effect of increasing 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels was unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Changes in FGF23 in 26 adults undergoing 6-hour (1-34) PTH infusion were examined, focusing particularly on the effects of PTH on FGF23 in the early period of infusion before sustained increases in 1,25(OH)(2)D.
RESULTS: FGF23 levels declined in parallel with serum phosphate during infusion (P<0.05 for both), with both analytes decreasing within the first hour and reaching their respective nadirs at 6 hours. These changes were observed despite no change in 1,25(OH)(2)D levels during the first hour and a significant increase in 1,25(OH)(2)D from baseline after 6 hours (P<0.001). There were no differences in these responses by race. However, modest racial differences in the phosphaturic response to (1-34) PTH were observed (P=0.04 for interaction), with a higher rate of increase in fractional phosphate excretion in blacks than in whites.
CONCLUSIONS: During short-term (1-34) PTH infusion, FGF23 levels decreased in parallel with serum phosphate levels and despite significant increases in 1,25(OH)(2)D. When coupled with the results of prior longer-term infusion studies, these findings suggest that acute increases in PTH initially act to suppress FGF23 secretion, perhaps to mitigate urinary phosphate losses, before the stimulatory effect of 1,25(OH)(2)D on FGF23 eventually begins to predominate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246283      PMCID: PMC3265347          DOI: 10.2215/CJN.06240611

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  30 in total

1.  Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.

Authors:  M Sridharan; J Cheung; A E Moore; M L Frost; W D Fraser; I Fogelman; G Hampson
Journal:  Calcif Tissue Int       Date:  2010-09-14       Impact factor: 4.333

2.  The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

Authors:  Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

3.  Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Authors:  Pieter Evenepoel; Björn Meijers; Liesbeth Viaene; Bert Bammens; Kathleen Claes; Dirk Kuypers; Dirk Vanderschueren; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-06       Impact factor: 8.237

4.  The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-jing Wang; Robert Elashoff; Barbara Gales; Mara J Horwitz; Andrew F Stewart; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

5.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

Authors:  Vardit Lavi-Moshayoff; Gilad Wasserman; Tomer Meir; Justin Silver; Tally Naveh-Many
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-04

6.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

7.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

8.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Authors:  Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

9.  Bone formation regulates circulating concentrations of fibroblast growth factor 23.

Authors:  Rana Samadfam; Christian Richard; Loan Nguyen-Yamamoto; Isabel Bolivar; David Goltzman
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

10.  Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men.

Authors:  Sherri-Ann M Burnett-Bowie; Maria P Henao; Melissa E Dere; Hang Lee; Benjamin Z Leder
Journal:  J Bone Miner Res       Date:  2009-10       Impact factor: 6.741

View more
  18 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Lack of FGF23 response to acute changes in serum calcium and PTH in humans.

Authors:  Katherine Wesseling-Perry; Hejing Wang; Robert Elashoff; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2014-07-25       Impact factor: 5.958

Review 3.  The dynamic skeleton.

Authors:  Anda Gonciulea; Suzanne Jan de Beur
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 4.  The PTH-Vitamin D-FGF23 axis.

Authors:  Jenny E Blau; Michael T Collins
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

5.  Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels.

Authors:  Vanessa M Knab; Braden Corbin; Olena Andrukhova; Julia M Hum; Pu Ni; Seham Rabadi; Akira Maeda; Kenneth E White; Reinhold G Erben; Harald Jüppner; Marta Christov
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

Review 6.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

Review 7.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

Review 8.  Novel bone endocrine networks integrating mineral and energy metabolism.

Authors:  Min Pi; L Darryl Quarles
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

9.  Calcium regulates FGF-23 expression in bone.

Authors:  Valentin David; Bing Dai; Aline Martin; Jinsong Huang; Xiaobin Han; L Darryl Quarles
Journal:  Endocrinology       Date:  2013-10-18       Impact factor: 4.736

Review 10.  A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.